immunotherapy

Research in Review

Biomarker Associated With Worse Survival Outcomes in Ovarian Cancer

06/20/2017

JCP Editors

Women with advanced ovarian cancer who express a certain tumor antigen will likely experience a shorter progression-free survival (PFS) and overall survival (OS) than those without the antigen, according to research...

Women...

06/20/2017

Journal of Clinical Pathways

Research in Review

CAR T-Cells Improve Outcomes in Multiple Myeloma

06/13/2017

JCP Editors

Multiple studies have demonstrated positive results for chimeric antigen receptor (CAR) T-cells in treating relapsed and refractory multiple myeloma, according to presentations at the 2017 ASCO Annual Meeting (June...

...

06/13/2017

Journal of Clinical Pathways

Research in Review

Novel Therapy Induces High Response Rate in Metastatic NSCLC

06/01/2017

JCP Editors

A novel antibody-drug conjugate is well tolerated and induces durable responses in pretreated patients with advanced non-small cell lung cancer (NSCLC), according to research published in the Journal of Clinical...

A...

06/01/2017

Journal of Clinical Pathways

Research in Review

Previous Radiotherapy Improves Response to Immunotherapy in NSCLC

05/30/2017

JCP Editors

Patients with advanced non-small cell lung cancer (NSCLC) who receive previous radiotherapy are more likely to benefit from immunotherapy than those patients without previous radiotherapy, according to research...

...

05/30/2017

Journal of Clinical Pathways

Research in Review

Biomarker-Driven Treatment Does Not Improve NSCLC Outcomes

05/15/2017

JCP Editors

Selecting patients with cyclooxygenase-2 (COX-2) expression by immunohistochemistry fails to improve survival outcomes in non-small cell lung cancer (NSCLC), according to research published in the Journal of Clinical...

...

05/15/2017

Journal of Clinical Pathways

Research in Review

Flu Vaccine May Cause Adverse Events for Lung Cancer Patients on Immunotherapy

05/03/2017

JCP Editors

Patients with lung cancer who are treated with immunotherapy may be at increased risk of severe adverse events after receiving the seasonal influenza vaccination, according to results of a study presented at the...

...

05/03/2017

Journal of Clinical Pathways

Interview

Payer Initiatives Drive Clinical Pathway Expansion

04/12/2017

JCP Editors

The future of clinical pathways largely depends on alternative payment models such as the Oncology Care Model sponsored by CMS, according to Edward Stepanski, PhD. ----- What inspired you to work in oncology? My...

The...

04/12/2017

Journal of Clinical Pathways

Department

Cost-Effectiveness Analysis Reveals Optimal Immunotherapy for Metastatic NSCLC

04/12/2017

JCP Editors

Recent research suggests a particular immunotherapy may be less costly and offer time savings compared with nivolumab for patients with metastatic non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors,...

Recent...

04/12/2017

Journal of Clinical Pathways

Interview

Clinical Pathways, Targeted Therapies Likely to Shape Future MZL Treatment

03/23/2017

JCP Editors

Journal of Clinical Pathways spoke with Peter Martin, MD, Lymphoma Service Chief, Weill Cornell Medicine and New York-Presbyterian, about the role of targeted therapies and clinical pathways in...

...

03/23/2017

Journal of Clinical Pathways

Research in Review

Combination Therapy Improves Efficacy of B-Cell Lymphoma Treatment

03/20/2017

JCP Editors

Combining two treatment strategies for the treatment of B-cell lymphoma may be more effective than either strategy alone, according to a study published in Cell Reports (February 28,...

...

03/20/2017

Journal of Clinical Pathways